Review Article
Psoriasis Arthritis and Elderly Patients
Kassi K*, Kouamé K, Vagamon B, Allou A, Kouassi A, Kourouma HS, Kouassi YI, Sangare A and Yoboue-Yao P
Corresponding Author: Kassi Komenan, MD, Department of Dermatology and infectiology, training and research unit of Medical sciences, University of Felix Houphouet Boigny of Abidjan
Received: June 24, 2017; Revised: June 29, 2017; Accepted: June 26, 2017
Citation: Kassi K, Kouamé K, Vagamon B, Allou A, Kouassi A, et al. (2017) Psoriasis Arthritis and Elderly Patients 151-154.
Copyrights: ©2017 Kassi K, Kouamé K Vagamon B, Allou A, Kouassi A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 2701

    Views & Citations
  • 1701

    Likes & Shares

Introduction: Psoriatic arthritis (PsA) is a heterogeneous disease that can involve a patient's peripheral and axial joints, entheses, skin and nails. PsA is more a gressive in geriatric patients with several co-morbidities. Systemic therapies that are indicated in PsA seem to have many side effects in geriatric patients.

Method: It was a systematic literature review via electronic search using Medline, Pubmed,  Pubmed  central,  Cochrane, Google scholar, web of science and embase, ACR reports.

Comment: PsA is a rare form of psoriasis. Genetic predisposition to psoriasis follows a multifactorial pattern. In senegal, a study conducted on 35 cases of psoriatic arthritis reported a family history in 57% of cases. With HIV epidemic, numerous reports of HIV infected patients with psoriatic arthritis were published. These genetic components and the Environmental  factors interact to lead to immune dysregulation. Recent studies on psoriatic arthritis suggested that IL-6 is necessary for production of antibodies specific for joint components (autoimmune phase) and TNF is necessary for generation of arthritis (inflammation phase). Psoriatic arthritis is traditionally defined as an inflammatory, rheumatoid factor-negative arthritis associated with psoriasis.

Due to the absence of specific biological markers for psoriatic arthritis, many tools have been recommended to diagnose PsA. Before the introduction of biotherapy, sulfasalazine and methotrexate were the most  used,  and  study drugs  in  peripheral forms of PsA patients. Biological therapies, mainly TNF inhibitors, have greatly improved the ability of clinicians to treat the various manifestations of PsA. Their side effects limited their use in geriatric patients, due to senescence, and co-morbidity associated with.

Conclusion: PsA impact negatively their quality of life and self care. Systemic treatments like TNF-antagonists that are recommended to treat PsA have many side effects in this population group. Therefore, it should carefully be used.

Key words: Psoriasis, Psoriatic arthritis, Clinic and Diagnosis, Management

1. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, et al. (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 50: 1939-19350.

2. Michet CJ (2004) Update on psoriasis arthritis. Int J Dermatol 43: 479-481

3. Dougados M, van der Linden S, Juhlin R (1991) The European Spondyloarthropathy Study Group. Preliminary Classification of Spondyloarthropathy. Arthritis Rheum 34: 1218-1227.

4. Fournié B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, et al. (1999) Proposition de critères de classification du rhumatisme psoriasique. Etude préliminaire de 260 patients. Rev Rhum 66: 513-524.

5. Ouédraogo DD, Meyer O (2012) Psoriasis Athritis in Sub Saharan. Africa. Joint Bone Spine 79: 17-19.

6. Gelfand JM, Stern RS, Nijsten T (2005) The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 52: 23-26.

7. Salliot C, Dernis E, Lavie F, Cantagrel A, Gaudin P, et al (2009) Diagnosis of peripheral psoriatic arthritis: Recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine 76: 532-539 

8. Goupille P (2005) Psoriatic arthritis. Joint Bone Spine 72: 466-470 

9. Raboobee N, Aboobaker J, Jordaan HF, Sinclair W, Smith JM, et al. (2010) Guideline on the management of psoriasis in South Africa. S Afr Med J 100: 255-282.

10. Kassi K, Djeha D, Gbery IP, Kouame K, Sangare A (2016) Psoriasis in elderly patients in the Côte d’Ivoire: sociodemographic, clinical, and therapeutic aspects, and follow-up. Int J Dermatol 55: e83-e86

11. Ouédraogo DD, Tiéno H, Kaboré H (2009) Ankylosing spondylitis in rheumatology patients in Ouagadougou (Burkina Faso). Clin Rheumatol 28: 1375-1377.

12. Diallo S, Ndongo S, Pouye A (2016) Spondylarthrite ankylosante : étude de 141 cas au Sénégal. Rev Rhum 2008 75: 1005-1106

13. Jensen P, Skov L (2009) Psoroasis and obesity. Dermatol 232: 633-639. 

14. Michalak-Stoma A, Pietrzak A, Szepietowski JC, Zalewska-Janowska A, Paszkowski T, et al. (2011) Cytokine network in psoriasis revisited. Eur Cytokine Netw 22: 160-168.

15. Zhu KJ, Zhang C, Li M, Zhu CY, Shi G, et al. (2013) Leptin levels in patients with psoriasis: a meta-analysis. Clin Exp Dermatol 38: 478-483.

16. Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T (2012) Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 79: 85-87.

17. Iwakura Y, Nakae S, Saijo S (2008) The roles of IL-17A in inflammatory immune responses and host defence against pathogens. Immunol Rev 226: 57-79.

18. Ramonda R, Puato M, Punzia L, Rattazzi M, Zanon M, et al. (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study. Joint Bone Spine 81: 421-425.

19. Hansson GK (2005) Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.

20. Enas A, Attia S, Khafagy A, Abdel-Raheem S, Fathi S, Saad AA (2011) Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. Int J Dermatol 50: 30-35

21. Ouédraogo DD, Lompo CP, Tiéno H (2010) Manifestations rhumatologiques des personnes vivant avec le virus de l’immunodéficience humaine, traitées par antirétroviraux: étude prospective de 366 malades au Burkina Faso. Med Trop 70: 345-348.

22. Monar N, Willis-Owen SA, Maurer T (2010) HIV associated psoriasis pathogenesis, clinical features and management. Lancet Infect Dis 10: 470-478. 

23. Han C, Robinson Jr DW, Hackett MV (2006). Cardiovascular disease and risk fac-tors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosingspondylitis. J Rheumatol 33: 2167-2172.

24. Maharaj AB, Govender J, Maharaj K, Rajkaran M, Paul P (2015) Tak Summary of Sensitivity and Specificity for Psoriatic Arthritis in a South African Cohort according to Classification Criteria. J Rheumatol 42: 6.

25. Sorianoj ER (2015) Defining Remission in Psoriatic Arthritis: Are We Getting Closer? Rheumatol; 42: 907-908. 

26. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356: 385-390.

27. Paccou J, Wendling D (2015) Current treatment of psoriatic arthritis: Update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis. Joint Bone Spine 82: 80-85.

28. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective to target for treatment. Ann Rheum Dis 69: 48-53.

29. Di Minno MN, Peluso R, Iervolino S (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 65: 141-147. 

30. 30- Tam LS, Li EK, Shang Q (2011). Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 70: 705-706. 

31. Ritchlin CT, Haas-Smith SA, Li P (2003) Mechanisms of TNF-a and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111: 821-831. 

32. Stolina M, Adamu S, Ominsky M (2005). RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 20: 1756-1765.

33. Hofbauer LC, Shoppet M, Christ M (2006) Tumor necrosis factor a-related apoptosis-inducing ligand and osteoprotegrin in serum levels in psoriatic arthritis. Rheumatol 45: 1218-1222.

34. Glad man D, Stafford Brady F, Chang C, Lewandowski K, Russell M (1990) Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 17: 809-812. 

35. McHugh N, Balachrishnan C, Jones A (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-year prospective study. Rheumatol 42: 778-783.

36. Zangger P, Esufali Z, Gladman D, Bogoch E (2000) Type and outcome of reconstructive surgery for different patterns of psoriatic arthritis. J Rheumatol 27: 967-974.

37. Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E (2017) Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun 76: 21-37.

38. Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L (2013) Adherence to Medication in Patients With Psoriasis. A systematic literature review. Br J Dermatol 168: 20-31.

39. Grisar J, Bernecker PM, Aringer M (2002) Ankylosing spondylitis, psoriatic arthritis and reactive arthritis show increased bone resorption,

but differ with regard to bone formation. J Rheumatol 29: 1430-1436.

40. Lavie F, Salliot C, Dernis E, Pierre PC, Schaeverbeke T, et al. (2009) Prognosis and followup of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 76: 540-546.

41. Ujfalussy I, Koo E (2003) Measurement of disease activity in psoriatic arthritis. Z Rheumatol 62: 60-65.